Form 4 for HAE HAEMONETICS CORP
Accepted 2022-08-08 00:00:00 ET · period of report 2022-08-05 · accession 0001127602-22-020700 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-08 | 2022-08-05 | HAE | Johnson Lloyd Emerson | Dir | A - Grant | — | +2,730 | 5,807 | +89% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-05 | A | A | 2,730 | — | 5,807 | D | — | — | (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |